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Introduction
Lung cancer is the most common cancer-related death 
in both men and women in all over the world (Siegel 
et al., 2013; Siegel et al., 2014). For diagnostic and 
therapeutic purposes, two main groups of lung cancer are 
distinguished: small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC) (Ettinger et al., 2012; 
Kalemkerian et al., 2013). NSCLC that represents nearly 
80% to 85% of all lung cancer, is a highly heterogeneous 
group including: squamous cell carcinoma (SCC), 
adenocarcinoma (ADC), and large cell carcinoma (LCC) 
(Ettinger et al., 2012). SCLC, which accounts for 15-
20% of all lung cancers, exhibits a highly aggressive and 
metastatic potential that NSCLC (Kalemkerian et al., 
2013). The 5-year survival rates in all stages of lung cancer 
remains only 15% and more than half of the patients at 
diagnosis (54%) have advanced disease namely distant 
stage or metastasis (Ettinger et al., 2012; Siegel et al., 
2013; Siegel et al., 2014). These catastrophic mortalities 
and morbidities, as well as, short-term survival of patients’ 
high indicated that there is an urgent necessity for finding 
reliable prognostic marker(s) and new agent(s) for targeted 
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Abstract
 Background: Extensive efforts have been made to investigate c-KIT expression in lung cancer specimens and 
its correlation with clinical outcomes, but the issue remains unresolved. Thus, this study will be conducted to 
clarify the prognostic value of c-KIT expression in lung cancer patients. Materials and Methods: We will search 
Pubmed, SCOPUS, and ISI web of sciences with no restriction of language. Studies with any design (except case 
reports or case series) evaluating correlations of c-KIT expression with survival or outcome in patients with lung 
cancer will be included. The outcome measures will include all types of survival indexes, including overall survival 
rate and disease free survival using Kaplan-Meier analysis and hazard ratios. Study selection and data extraction 
will be performed by two independent researchers. Quality assessment (assessment of risk of bias) and data 
synthesis will be implemented using Stata software version 11.1. Results: No ethical issues are predicted. These 
findings will be published in a peer-reviewed journal and presented at national and international conferences. 
Conclusions: This systematic review protocol is registered in the PROSPERO International Prospective Register 
of Systematic Reviews, registration number = CRD42015023391. 
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therapy in lung cancer patients. 
A wide spectrum of biomarkers has been tested for 
their prognostic and predictive values in lung cancer 
and some have used in clinical applications, including 
K-RAS, EGF-R, and thyroid transcription factor-1 (TTF1) 
(Mascaux et al., 2005; Berghmans et al., 2006; Nakamura 
et al., 2006; Berghmans et al., 2011; Gazdar and Schiller 
2011). In the two last decades, proto-oncogene c-KIT has 
been great of attention for a prognostic role in several 
malignant tumors, especially lung cancer (Grossi et al., 
2010; Medinger et al., 2010; Herpel et al., 2011; Lu et 
al., 2012; Xiao et al., 2014; Matsumura et al., 2015). The 
proto-oncogene c-KIT, also known as CD117, encodes 
a transmembrane protein that belongs to tyrosine kinase 
receptor type III (Chabot et al., 1988; Ashman, 1999). 
c-KIT binds its ligand, that’s called stem cell factor (SCF), 
and plays important roles in cell survival, proliferation, 
and differentiation (Edling and Hallberg 2007). 
The correlation between c-KIT expressions and 
clinicopathlogical parameters including disease free 
survival (DFS) or overall survival (OS) was explored in 
lung cancer patients, but there is no consensus concerning 
the prognostic role of c-KIT these patients (Mascaux 
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et al., 2005; Berghmans et al., 2006; Nakamura et al., 
2006; Berghmans et al., 2011; Gazdar and Schiller 
2011). Although a more recent attempt to investigate the 
prognostic value of c-KIT expression in cancer patients 
(Zhao et al., 2014), this systematic review, for the first 
time, will conduct to evaluate the prognostic accuracy of 
c-KIT in the prognosis of patients with lung cancer using 
comprehensive search of several databases. 
Objectives 
The primary objective of the current systematic review 
is to assess the prognostic accuracy of c-KIT in lung cancer 
patients using survival measure. The secondary objectives 
will be to determine prognostic accuracy of c-KIT in 
different subtypes of lung cancer, including SCC, ADC, 
and LCC in NSCLC group and SCLC group, as well as, 
determination of the heterogeneity and its potential source. 
Methods 
The protocol of this systematic review has 
been registered on PROSPERO website (www.crd.
york.ac.uk/PROSPERO) (PROSPERO registration 
number=CRD42015023391). This systematic review 
protocol has been developed based on the Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) statement guidelines (Liberati et 
al., 2009).
Criteria for considering studies for this 
systematic review.
Types of studies; All observational studies (case-
control, cross sectional, and cohort) have been evaluated 
the association between c-KIT expression and the clinical 
prognosis of lung cancer will include in the current study. 
Participants
The studies will include in this systematic review 
that evaluated the association between c-KIT expression 
and the clinical prognosis or survival outcome (disease 
free survival or overall survival) of patients with lung 
cancer. Both of gender (female and male), participants 
with any limitation of age, patients with no preoperatively 
treatment of all histological grades (well, moderate, and 
poor) and stages (I, II, III, and IV) will be included in 
the current systematic review. In addition lymph node 
involvement and metastasis data will be recorded without 
any limitation. 
Index Test 
In the current study, c-KIT expression will define by 
immunohistochemistry (IHC) or tissue microarray (TMA) 
with all scoring systems, including intensity of staining, 
percentage of positive cells, and H-score (McCarty et 
al., 1985). Evaluation of c-KIT using flow cytometry or 
molecular-based approaches such as polymerase chain 
reaction (PCR) were excluded from the current systematic 
review. 
Gold standard 
All types of survival indexes, including survival rate, 
disease free survival, Kaplan-Meier analysis, and hazard 
ratio will be included in the current systematic review. 
Target Condition 
Prognosis of lung cancer patients will be target 
condition. 
Outcomes 
The our primary outcomes will be all types of survival 
indexes, including survival rate, disease free survival, 
Kaplan-Meier analysis, and hazard ratio. In addition, the 
secondary outcomes the current systematic review will 
be to determine prognostic accuracy of c-KIT in different 
subtypes of lung cancer, including SCC, ADC, and LCC in 
NSCLC group and SCLC group, as well as, determination 
of the heterogeneity and its potential source.
Search Methods for Identification of Studies 
The electronic databases Medline, SCOPUS, and ISI 
web of sciences will be searched to end of Jun 2015. 
Searching Strategies of the Medline Database
MeSH tags were found in the MEDLINE subset of 
PubMed. Then, we used the syntax number 3 for selecting 
the relevant clinical trials. 
i). c-KIT; ii). CD117; iii). p145; iv). Stem cell factor; 
v). c- KIT OR CD117 OR p145 OR stem cell factor; vi). 
c- KIT [tiab] OR CD117 [tiab] OR p145 [tiab] OR stem 
cell factor [tiab]; vii). (c-KIT [tiab] OR CD117 [tiab] 
OR p145 [tiab] OR stem cell factor [tiab]) AND (lung or 
pulmonary) (Table 1). 
Searching Strategies of the SCOPUS
The search terms and syntax for SCOPUS will be 
as follow (Table 2): i). (TITLE-ABS-KEY (c-KIT) OR 
Table 1. Search Syntax in Pubmed 
Syntax no. Syntax
     1 c-KIT OR CD117 OR p145 OR stem cell factor
     2 c- KIT [tiab] OR CD117 [tiab] OR p145 [tiab] OR stem cell factor [tiab]
     3 (c- KIT [tiab] OR CD117 [tiab] OR p145 [tiab] OR stem cell factor [tiab]) AND (lung or pulmonary)
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TITLE-ABS-KEY (CD117) OR TITLE-ABS-KEY (p145) 
OR TITLE-ABS-KEY (stem cell factor); ii). TITLE-ABS-
KEY (c-KIT) OR TITLE-ABS-KEY (CD117) OR TITLE-
ABS-KEY (p145) OR TITLE-ABS-KEY (stem cell 
factor) AND TITLE-ABS-KEY (lung) OR TITLE-ABS-
KEY (pulmonary); iii). (TITLE-ABS-KEY (c-KIT) OR 
TITLE-ABS-KEY (CD117) OR TITLE-ABS-KEY (p145) 
OR TITLE-ABS-KEY (stem cell factor) AND TITLE-
ABS-KEY (lung) OR TITLE-ABS-KEY (pulmonary) 
AND TITLE-ABS-KEY (cancer) OR TITLE-ABS-KEY 
(tumor) OR TITLE-ABS-KEY (carcinoma) OR TITLE-
ABS-KEY (neoplasm) OR TITLE-ABS-KEY (neoplasia); 
iv). (TITLE-ABS-KEY (c-kit) OR TITLE-ABS-KEY 
(cd117) OR TITLE-ABS-KEY (p145) OR TITLE-ABS-
KEY (stem cell factor) AND TITLE-ABS-KEY (lung) OR 
TITLE-ABS-KEY (pulmonary) AND TITLE-ABS-KEY 
(cancer) OR TITLE-ABS-KEY (tumor) OR TITLE-ABS-
KEY (carcinoma) OR TITLE-ABS-KEY (neoplasm) OR 
TITLE-ABS-KEY (neoplasia) AND TITLE-ABS-KEY 
(prognosis) OR TITLE-ABS-KEY (disease free survival) 
OR TITLE-ABS-KEY (outcome) OR TITLE-ABS-KEY 
(prognostic)
Data Collection 
Studies identified by the final syntax in electronic 
searches screened with the two authors (RR and EK) 
will independently screen titles and abstracts to identify 
potentially relevant studies. Disagreements will be 
resolved by discussion between the two authors (RR and 
EK). After the screening, we will retrieve full texts of 
potentially eligible studies to assess whether the individual 
studies fulfill the inclusion criteria. Two authors (RR and 
EK) will independently extract data from the selected 
original articles. If there are any discrepancies, it will be 
resolved by consensus between the two authors. As shown 
in figure 1, the study selection is performed based on the 
PRISMA flow diagram. 
Data Analysis 
Statistical analysis of data will be performed using 
Stata software version 11.1 (StataCorp LP, College 
Station, TX, USA). The association of c-KIT expression 
and clinicopathological features as well as DFS or OS will 
be assessed using forest plot. Study heterogeneity will 
be measured using the Q test and I2 test. For evaluating 
source of heterogeneity, sub-group analysis and meta-
regression will be used. The potential for publication bias 
was assessed using funnel plot, the Begg rank correlation 
method, and the Egger weighted regression method. A 
p-value of ≤0.05 will be considered to be statistically 
significant.
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